Path to approval proves rocky for copycat biodrugs

Meredith Wadman

Nature, 2005, vol. 438, issue 7065, 154-155

Abstract: Attempts to copy the first generation of biotechnology drugs are facing fierce resistance, as Meredith Wadman reports.

Date: 2005
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/438154a Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:438:y:2005:i:7065:d:10.1038_438154a

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/438154a

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().